N6-甲基腺嘌呤修饰在中枢神经系统疾病及相关治疗药物中的作用
Role of N6-methyladenosine modification in central nervous system diseases and related therapeutic agents.
作者信息
Lv Junya, Xing Lijuan, Zhong Xin, Li Kai, Liu Mingyan, Du Ke
机构信息
School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang 110122, China.
Precision Laboratory of Panjin Central Hospital, Panjin 124000, China.
出版信息
Biomed Pharmacother. 2023 Jun;162:114583. doi: 10.1016/j.biopha.2023.114583. Epub 2023 Mar 28.
N6-methyladenosine (m6A) is a ubiquitous mRNA modification in eukaryotes. m6A occurs through the action of methyltransferases, demethylases, and methylation-binding proteins. m6A methylation of RNA is associated with various neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), depression, cerebral apoplexy, brain injury, epilepsy, cerebral arteriovenous malformations, and glioma. Furthermore, recent studies report that m6A-related drugs have attracted considerable concerns in the therapeutic areas of neurological disorders. Here, we mainly summarized the role of m6A modification in neurological diseases and the therapeutic potential of m6A-related drugs. The aim of this review is expected to be useful to systematically assess m6A as a new potential biomarker and develop innovative modulators of m6A for the amelioration and treatment of neurological disorders.
N6-甲基腺苷（m6A）是真核生物中普遍存在的一种mRNA修饰。m6A的发生是通过甲基转移酶、去甲基酶和甲基化结合蛋白的作用。RNA的m6A甲基化与多种神经疾病相关，包括阿尔茨海默病（AD）、帕金森病（PD）、抑郁症、脑中风、脑损伤、癫痫、脑动静脉畸形和神经胶质瘤。此外，最近的研究报告称，m6A相关药物在神经疾病治疗领域引起了相当大的关注。在此，我们主要总结了m6A修饰在神经疾病中的作用以及m6A相关药物的治疗潜力。本综述的目的有望有助于系统评估m6A作为一种新的潜在生物标志物，并开发用于改善和治疗神经疾病的m6A创新调节剂。
Zotero 插件